Trial Profile
Open-label single arm phase II study on pembrolizumab for recurrent primary central nervous system lymphoma (PCNSL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
- 11 May 2022 This trial has been discontinued in Austria (Date of the global end of the trial : 15-Oct-2019), according to European Clinical Trials Database record.
- 03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 10 Mar 2016 New trial record